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Abstract
Background: Antipsychotics (APs) have been associated with risk of torsade de Pointes (TdP). This has important
public health implications. Therefore, (a) we exploited the public FDA Adverse Event Reporting System (FAERS) to
characterize their torsadogenic profile; (b) we collected drug utilization data from 12 European Countries to assess
the population exposure over the 2005-2010 period.
Methods: FAERS data (2004-2010) were analyzed based on the following criteria: (1) ≥4 cases of TdP/QT
abnormalities; (2) Significant Reporting Odds Ratio, ROR [Lower Limit of the 95% confidence interval>1], for TdP/QT
abnormalities, adjusted and stratified (Arizona CERT drugs as effect modifiers); (3) ≥4 cases of ventricular
arrhythmia/sudden cardiac death (VA/SCD); (4) Significant ROR for VA/SCD; (5) Significant ROR, combined by
aggregating TdP/QT abnormalities with VA and SCD. Torsadogenic signals were characterized in terms of signal
strength: from Group A (very strong torsadogenic signal: all criteria fulfilled) to group E (unclear/uncertain signal: only
2/5 criteria). Consumption data were retrieved from 12 European Countries and expressed as defined daily doses per
1,000 inhabitants per day (DID).
Results: Thirty-five antipsychotics met at least one criterium: 9 agents were classified in Group A (amisulpride,
chlorpromazine, clozapine, cyamemazine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone). In 2010, the
overall exposure to antipsychotics varied from 5.94 DID (Estonia) to 13.99 (France, 2009). Considerable increment of
Group A agents was found in several Countries (+3.47 in France): the exposure to olanzapine increased across all
Countries (+1.84 in France) and peaked 2.96 in Norway; cyamemazine was typically used only in France (2.81 in
2009). Among Group B drugs, levomepromazine peaked 3.78 (Serbia); fluphenazine 1.61 (Slovenia).
Conclusions: This parallel approach through spontaneous reporting and drug utilization analyses highlighted drug-
and Country-specific scenarios requiring potential regulatory consideration: levomepromazine (Serbia), fluphenazine
(Slovenia), olanzapine (across Europe), cyamemazine (France). This synergy should be encouraged to support
future pharmacovigilance activities.
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Introduction
Antipsychotics (APs) represent a heterogeneous
pharmacological class in terms of molecular targets [1],
although several studies have challenged whether this
multifaceted profile actually translates into clinical differences
(i.e., effectiveness) between first- and second- generation
agents (FGAs and SGAs), in the past referred to as “typical”
and “atypical” drugs, respectively [2-4]. This uncertainty poses
emerging clinical implications for psychiatrists when
considering the appropriate therapy, which should be tailored
to the individual [5-7].
The interest on this therapeutic class has strongly increased
in the last two decades for several reasons, especially when
new SGAs became available and were presented as having
better benefit-risk profiles as compared to the older FGAs,
namely a reduced risk of extra-pyramidal symptoms. Therefore,
increased consumption was recorded throughout all age
groups, ethnic groups and therapeutic indications, including off-
label use [8,9]. The rapid changes in the uptake of these drugs
require adequate monitoring of actual adverse effects in the
real population to support future decision making. Thus,
spontaneous reporting of adverse events represents a ready-
to-use source of data to be analyzed for an early and timely
identification of risks [10].
From a safety standpoint, the key topic has shifted from
extra-pyramidal side effects to the novel aspect of the “cardio-
metabolic” risk and cardiovascular toxicity, for which great
interest has recently emerged [11]. Whilst there is consensus in
assessing the metabolic risk and related cardiovascular
complications (e.g., olanzapine is more strongly associated
with weight gain as compared to other SGAs [12]), QT
prolongation and subsequent arrhythmia-related events (i.e.,
Torsade de Pointes, TdP) represent the most important cardiac
aspect of antipsychotics [13,14]. In the past, SGAs were
perceived as having a favorable arrhythmogenic profile;
however, this benefit has been recently challenged by different
pharmacovigilance analyses on spontaneous reporting
systems [15-17], which have also been confirmed by
subsequent pharmacoepidemiological studies [18,19]. As a
consequence, public lists of drugs with TdP liability collated by
the Arizona CERT (http://crediblemeds.org/, a reference
standard for clinicians) are constantly being updated and now
include a number of antipsychotics.
Data on antipsychotic use can provide an additional
perspective to regulators and clinicians in assessing the
possible consequences of side effects of drugs by mapping the
level of risk associated with antipsychotic exposure. Although
several drug utilization studies have been conducted with
different aims, especially in the US to assess the impact of
regulatory warnings on the prescription pattern of
antipsychotics [20-23], to the best of our knowledge, no
detailed cross-national comparisons have been recently carried
out in Europe.
On these grounds, the principal aims of this study were
twofold: 1) to characterize torsadogenic signals of
antipsychotics emerging from the largest publicly available
pharmacovigilance database, the FDA Adverse Event
Reporting System (FAERS); 2) to offer the public health
perspective of these pharmacovigilance signals (i.e., the
population exposure) by collecting drug utilization data from 12
European Countries. Subsequently, notify the authorities in
pertinent countries where there are potential concerns.
Methods
Ethics Statement
All data analyses performed in this retrospective study are
based on anonymized data, which did not allow the precise
identification of individual patients. The study dealt with two
independent data sources, namely (a) spontaneous reports,
which are publicly available from the FAERS database and (b)
drug utilization data, which can be accessed by other
researchers only upon request to relevant personnel.
Therefore, submission to and approval by the Institutional
Review Board was not required.
Pharmacovigilance data source
By virtue of its large population coverage (including all US
reports and rare/serious events from European Countries) and
free availability since 2004, FAERS is an attractive source to
detect emerging safety signals and a valuable tool to explore
the worldwide reporting pattern of rare Adverse Drug Reactions
(ADRs) such as TdP [15]. As a matter of fact, approximately
800,000 reports are entered into FAERS each year, of which
almost a half is submitted by non-US Countries (e.g., European
areas) and consumers. In addition, interest is emerging in
using FAERS to obtain reliable within-class comparisons [24].
Before performing the analysis, a number of issues have
been considered to obtain a reliable dataset: drug and event
codification through ad hoc and standardized (MedDRA)
archives, respectively; duplicate detection; management of
missing data [25]. As previously detailed [15,26], the
2004-2010 period was analyzed through a record-linkage
strategy of different files: DEMO (demographic data), DRUG
(the analysis was restricted to APs reported as suspect or
interacting), REACTION and OUTCOME (to assess the
seriousness of the event; i.e., whether or not the ADR resulted
in death or life-threatening conditions).
Organizing pharmacovigilance data
In a recent study, we described the consensus process to
define the torsadogenic potential of drugs and extract relevant
cases of interest [27]. In summary, a wide range of clinical
events with decreasing drug-attributable risk for TdP was
collected: 1) TdP, 2) QT interval abnormalities (including QT
prolongation), 3) Ventricular Arrhythmia (VA, including
ventricular tachycardia and fibrillation) and 4) Sudden Cardiac
Death (SCD). Building on this previous approach, in the
present study, these clinical events were combined as follows:
(a) TdP reports were analyzed with QT abnormalities as they
are strongly intertwined with a high degree of drug-attributable
risk (TdP is a so-called designated medical event, i.e., a rare
and serious event with high drug-attributable component [28]);
(b) VA reports were separately analyzed with SCD events as
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they are not strictly correlated with TdP and carry a reduced
degree of drug-attributable risk [29].
Based on these events and considering the clinical scenario
in which TdP usually occurs (i.e., the so called “reduced
repolarization reserve” due to multiple risk factors such as
concomitant drugs with TdP liability [30]), the following criteria/
parameters (with relevant thresholds) were defined to analyze
pharmacovigilance data:
1 Number of cases of TdP/QT abnormalities (at least 4 cases);
2 Significant Reporting Odds Ratio, ROR (i.e., Lower Limit of
the 95%CI>1 and at least 4 cases) for TdP/QT abnormalities,
adjusted for confounders (e.g., concomitant Class I/III
antiarrhythmic drugs) in the stratum without drugs listed by
Arizona CERT (effect modifiers) [27];
3 Number of cases of VA/SCD (at least 4 cases);
4 Significant ROR for VA/SCD, unadjusted and un-stratified;
5 Significant unadjusted and un-stratified ROR that persists
throughout a cumulative approach (i.e., from TdP to SCD).
In order to analyze drug utilization data in a public health
perspective, the following groups were created to characterized
signals in terms of strength, based on the consistency of the
aforementioned criteria:
A Antipsychotics with very strong torsadogenic signal (i.e.,
consistency among all criteria): all criteria exceeded relevant
thresholds;
B Antipsychotics with strong torsadogenic signal (i.e., the
majority of criteria are fulfilled): at least 4 out of 5 criteria
exceeded relevant thresholds;
C Antipsychotics with weak/moderate torsadogenic signal (i.e.,
criteria not homogeneously fulfilled): at least 3 out of 5 criteria
exceeded relevant thresholds;
D Antipsychotics with unclear/uncertain torsadogenic signal
(i.e., the majority of criteria are not fulfilled): only 2 (or less) out
of 5 criteria exceeded relevant thresholds.
Drug utilization data collection
After safety signals are identified from FAERS, drug
utilization data allow us to map the risk derived from exposure
to antipsychotic drugs in each Country. Collection of drug
utilization data on antipsychotics requires careful consideration
of the available sources across Europe, including
characteristics of databases (e.g., data quality, population
coverage, data access), limitations and aims of the research
[31]. In this study, drug utilization data were collected from
administrative databases through health authorities and health
insurance personnel across Europe. Consistent and reliable
data were obtained from twelve European Countries, which
allowed adequate estimation of European population exposure
and represented differences in geography and financing of
healthcare: they comprised Northern (Sweden, Norway and
Scotland), Southern-Western (Spain [Catalonia], Austria,
France, Italy) as well as Central-Eastern (Croatia, Serbia,
Slovenia, Estonia, Lithuania) European Countries and regions.
In addition, differences in the method of financing healthcare:
taxation (Italy, Norway, Scotland, Spain [Catalonia], Sweden)
and health insurance based (Austria, Croatia, Estonia, France,
Lithuania, Serbia and Slovenia).
Total dispended data (ATC code: N05A, excluding Lithium)
were expressed as defined daily doses (DDD) per 1,000
inhabitants per day (DDD/TID, now referred to as DID) for the
2005-2010 period (with some exceptions detailed in the
relevant table). Despite limitations, the DDD system is a
recognized tool for standardizing antipsychotic doses in drug
utilization research [32], and is currently recommended by the
WHO for international drug utilization studies [33]. In the
analyses, we considered a detectable use of at least 0.01 DID.
The mean DID value was used to estimate the actual
population exposure over the period of interest, in line also with
pharmacovigilance data. A time trend analysis was also carried
out, where appropriate. Data were re-validated with data
providers to enhance their accuracy. A structured inventory of
drug consumption databases available across Europe (with
relevant details on data access and characteristics) has been
recently provided within the PROTECT
(Pharmacoepidemiological Research on Outcomes of
Therapeutics by a European Consortium) project (http://
www.imi-protect.eu/frameworkRep.shtml). Moreover, Table S1
provided details of the databases used in our study. With only a
few exceptions, administrative databases regards reimbursed
prescriptions in ambulatory care and covered the entire
population.
Results
Pharmacovigilance analyses
Over the 7-year-period of the analysis, 37 antipsychotics
received at least one report in FAERS for the events of interest;
35 of them fulfilled at least one criterium for signal
characterization. Table 1 provides a synopsis of
pharmacovigilance criteria and their combination for signal
characterization. Group A (i.e., antipsychotics that fulfilled all
criteria) included 9 agents, 6 of which are SGAs. Of these, only
cyamemazine is not included in any Arizona CERT lists (as of
January 4th, 2013). Two agents were already included in List I
(i.e., chlorpromazine and haloperidol), 5 SGAs in List II,
amisulpride as the only compound in List III. Group B included
7 drugs (all FGAs, except droperidol), with only droperidol
listed by Arizona CERT in List I. Group C comprised 13 agents,
with paliperidone and pimozide recorded in Arizona CERT
Lists. Eight antipsychotics were categorized in Group D.
Quetiapine (18,070), olanzapine (11,622) and clozapine
(10,082) were the most frequently reported overall and also
received the highest number of reports for the events of
interest, namely group TdP/QT and VA/SCD (Table 2).
Notably, for most antipsychotics, also European reports have
been submitted to FAERS and, in most of the cases, European
Countries for which drug utilization were available have largely
contributed (e.g., France). Concerning Group A drugs,
cyamemazine (79.8%) and amisulpride (73.5%) received the
highest proportion of reports from Europe. By contrast,
quetiapine (75.7%) and risperidone (71.3%) mainly received
US reports. As regards Group B agents, with the exception of
fluphenazine, reports were mostly submitted by European
Countries. Paliperidone and aripiprazole (Group C) received
the majority of reports from US, whereas Group D agents from
Torsadogenic Risk of Antipsychotics
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Europe (especially pipamperone and melperone). France,
Germany and UK were the most frequent European reporter
Countries.
The full original data, including the results of the different
disproportionality approaches (i.e., ROR values for each
antipsychotic drug according to the event of interest), are
provided as supplementary material (Table S2). These data
have been used to characterize the strength of the
pharmacovigilance signal.
Drug Utilisation analyses
In 2010, the total exposure to antipsychotics (including, for
instance, dixyrazine, thioridazine and sertindole, not included in
or detected by the pharmacovigilance analysis) varied by a
factor of approx 2, between Countries with the lowest (5.94 DID
in Estonia) and highest (12.89 DID in Spain) use. In 2009,
France peaked 13.99 DID (the latest available year of data
collection). In all Countries, antipsychotic use increased over
the period of interest, albeit with different trends among the
different Countries. The increment was greatest in Central and
Table 1. Synopsis of results from FAERS (2004-2010) according to criteria combined for signal characterization.
Antipsychotic Criterium 1 Criterium 2 Criterium 3 Criterium 4 Criterium 5 AZCERT List # Signal characterization
cyamemazine x x x x x  A
olanzapine x x x x x II A
amisulpride x x x x x III A
chlorpromazine x x x x x I A
clozapine x x x x x II A
haloperidol x x x x x I A
quetiapine x x x x x II A
risperidone x x x x x II A
ziprasidone x x x x x II A
bromperidol x  x x x  B
chlorprothixene x  x x x  B
droperidol x  x x x I B
fluphenazine x  x x x  B
levomepromazine x  x x x  B
prothipendyl x  x x x  B
zuclopenthixol x  x x x  B
paliperidone x x x   II C
aripiprazole x x x    C
pimozide x  x  x I C
flupentixol   x x x  C
loxapine   x x x  C
melperone   x x x  C
perazine   x x x  C
periciazine   x x x  C
perphenazine   x x x  C
pipamperone   x x x  C
prochlorperazine   x x x  C
sulpiride   x x x  C
zotepine   x x x  C
promazine   x  x  D
acepromazine   x    D
asenapine   x    D
tiapride   x    D
trifluoperazine   x    D
sultopride     x  D
levosulpiride       D
pipotiazine       D
Within each criterium, drugs are listed by considering the number of criteria fulfilled from 1 to 5 and the alphabetical order.
# based on the website http://crediblemeds.org/ (as of January 4th, 2013).
Only antipsychotics with at least one report for the event of interest are shown.
“X” indicates that the drug fulfilled relevant criterium.
doi: 10.1371/journal.pone.0081208.t001
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Eastern European countries (+3.09 DID in Lithuania, +3.03 in
Croatia) and especially in Serbia (+5.61 DID, +183%). This
potentially reflects more drugs being placed on the
reimbursement list, whereas in Northern European countries
the consumption was more stable (+0.35 in Norway, +0.43 in
Sweden) (Figure 1).
Table 3 provides an overview of drug utilization data on 37
antipsychotics arisen from the pharmacovigilance analyses and
Table 2. Overview of FAERS data with key information on reporter Country.
Antipsychotic TdP/QT cases VA/SCD cases Total reports $
US reports # (% of
tot. Reports)
EU* reports # (% of
tot. Reports) Top 5 European Reporter Countries (%)
cyamemazine 11 40 362 0.6 79.8 FRA (96.5); DNK (1.4); GER (1.0); UK (0.7); ITA (0.4)
olanzapine 189 712 11,622 43.8 26.6 FRA (23.3); UK (20.00); GER (18.3); SWI (7.4); SPA (4.2)
amisulpride 25 36 302 1.0 73.5 UK (31.5); FRA (28.4); GER (17.1); SWI (8.1); ITA (5.9)
chlorpromazine 14 69 611 28.3 20.3 FRA (47.6); UK (27.4); IRL (8.1); ITA (4.8); GRE (2.4)
clozapine 178 900 10,082 36.0 29.4 UK (58.1); GER (9.6); IRL (9.0); FRA (8.4); SWI (2.6)
haloperidol 125 239 3,582 20.6 50.9 FRA (30.2); ITA (20.7); GER (18.4); UK (8.7); SPA (6.9)
quetiapine 186 934 18,070 75.7 11.3 GER (25.4); UK (21.8); SWI (12.8); DNK (5.5); ITA (4.6)
risperidone 151 486 8,381 28.3 38.1 UK (25.1); FRA (25.0); GER (19.5); ITA (6.6); SPA (5.2)
ziprasidone 167 161 2,775 71.3 5.3 GER (37.0); SPA (11.6); ITA (8.2); DNK (6.2); GRE (4.8)
bromperidol 7 8 25  36.0 GER (55.6); BEL (33.3); FRA (11.1)
chlorprothixene 4 23 100 1.0 70.0 GER (51.4); DNK (21.4); SWI (7.1); NOR (4.3); SWE (2.9)
droperidol 10 20 131 26.0 37.4 FRA (85.7); UK (4.1); SWI (2.0); NOR (2.0); NLD (2.0)
fluphenazine 8 22 258 45.3 22.9 FRA (37.3); UK (25.4); CRO (20.3); SPA (6.8); ITA (5.1)
levomepromazine 6 39 272  61.8 FRA (47.6); SWI (13.1); UK (7.1); AUT (7.1); ITA (4.8)
prothipendyl 6 13 94  87.2 GER (75.6); AUT (12.2); DNK (7.3); ITA (2.4); FRA (2.4)
zuclopenthixol 6 16 112 3.6 73.2 FRA (31.7); UK (15.9); SWE (9.8); SWI (7.3); ITA (6.1)
paliperidone 11 46 1,702 77.2 13.4 GER (41.7); SPA (12.3); ITA (11.4); SWI (6.1); GRE (4.8)
aripiprazole 46 230 7,258 58.4 17.3 UK (28.2); FRA (24.8); GER (18.8); ITA (3.6); SWI (3.4)
pimozide 16 6 77 15.6 39.0 FRA (40.0); GER (23.3); UK (10.0); ITA (10.0); SPA (3.3)
flupentixol 2 9 84 2.4 76.2 SWI (21.9); GER (21.9); UK (18.8); FRA (10.9); DNK (9.4)
loxapine 3 22 171 11.7 70.8 FRA (97.5); DNK (2.5)
melperone ─ 5 37  81.1 GER (86.7); FRA (6.7); UK (3.3); SWE (3.3)
perazine ─ 8 52  59.6 GER (77.4); SWE (6.5); POL (6.5); FRA (3.2); DNK (3.2)
periciazine ─ 7 41  61.0 FRA (72.0); UK (24.0); DNK (4.0)
perphenazine ─ 13 134 47.8 24.6 UK (27.3); NOR (18.2); ITA (15.1); DNK (12.1); SPA (9.1)
pipamperone 1 15 145 2.8 88.3 GER (63.3); FRA (18.0); SWI (13.3); UK (2.3); DNK (2.3)
prochlorperazine 1 26 318 70.4 8.5 UK (77.8); IRL (11.1); SWI (3.7); FRA (3.7); DNK (3.7)
sulpiride 3 20 223 0.9 16.6 UK (32.4); FRA (24.3); GER (16.2); SPA (10.8); ITA (8.1)
zotepine ─ 9 32 3.1 9.4 GER (66.7); PRT (33.3)
promazine 3 5 48 4.2 70.8 SWI (50.0); ITA (29.4); UK (8.8); FIN (5.9); CRO (5.9)
acepromazine ─ 4 41 7.3 73.2 FRA (90.0); DNK (6.7); GER (3.3)
asenapine 2 7 623 100   
tiapride 1 7 95 3.2 75.8 FRA (79.2); ITA (5.6); GER (5.6); SWI (2.8); DNK (2.8)
trifluoperazine ─ 7 104 48.1 12.5 UK (84.6); GER (7.7); FIN (7.7)
sultopride 1 3 13    
levosulpiride 1 ─ 8 12.5 62.5 ITA (100)
pipotiazine ─ 1 7 14.3 85.7 FRA (83.3); UK (16.7)
$: excluding reports where antipsychotics were recorded as "concomitant". * including UK and Switzerland. # based on the information recorded in the field “Reporter
Country”. The remaining fraction is related to missing data and other non -US/non-EU Countries (e.g., Japan). ─: no cases detected.
AUT: Austria; CRO: Croatia; DNK: Denmark; EST: Estonia; FIN: Finland; FRA: France; GER: Germany; GRE: Greece; IRL: Ireland; ITA: Italy; NLD: Netherlands; NOR:
Norway; POL: Poland; PTR: Portugal; SCO: Scotland; SER: Serbia; SLO: Slovenia; SPA: Spain; SWI: Switzerland; UK: United Kingdom;
doi: 10.1371/journal.pone.0081208.t002
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expressed in terms of mean DID over the study period. The
mean exposure varied substantially: from France (12.92) and
Slovenia (10.62) to Estonia and Lithuania (5.07 and 5.04,
respectively). The mean use of SGAs was appreciably higher
than the mean use of FGAs in all Countries, with the largest
exposure to SGAs in Catalonia (Spain) (7.83).
Figure 2 provided the exposure to these 37 antipsychotics
according to their characterization for torsadogenic signal. This
time-trend analysis found that the overall utilization
substantially increased in all Countries, especially in Serbia
(+5.60) and France (+3.74). Only a limited increase in
utilization was observed among Northern European Countries
(+0.45 in Sweden, +0.51 in Norway). The consumption of
SGAs increased in all Countries (+3.79 in France), although
lower in Norway (+1.15) and Sweden (+0.67). By contrast, the
use of FGAs showed a positive trend only in Serbia (+4.25).
This positive trend in antipsychotic use was mainly driven by
the increase in utilization of Group A agents: from +3.47 in
France to +0.34 in Sweden, with substantial increment also in
Croatia (+2.71), Austria (+2.32) and Slovenia (+2.24). In 2010
Spain (Catalonia) was the Country with the highest exposure to
Group A agents (8.57); France ranked first in 2009 (10.25).
By contrast, the use of agents included in Group D was
irregular and very low across Europe. In 2010, the magnitude
of use was marked only in Croatia (1.62) and France (0.55).
Generally, decreased utilization was recorded across all
Countries, especially in Norway (-1.17) and Sweden (-0.76). An
increase was found only in Lithuania (+0.06).
There was generally limited use of antipsychotics included in
Group B, as compared to Group A. However, the 2010
exposure to levomepromazine was high in Serbia (3.78).
Appreciable use was also seen for fluphenazine, especially in
Slovenia (1.63 in 2010), Serbia (1.02) and France (0.92 in
2009). The consumption of zuclopenthixol was considerably
Figure 1.  Trends in antipsychotic utilization according to data availability.  AUT: Austria; CRO: Croatia; EST: Estonia; FRA:
France; ITA: Italy; LIT: Lithuania; NOR: Norway; SPA: Spain (Catalonia); SCO: Scotland; SER: Serbia; SLO: Slovenia; SWE:
Sweden; EMA: European Medicines Agency; FDA: Food and Drug Administration; FGA: first-generation antipsychotics; SGA:
second-generation antipsychotics; TdP: Torsades de Pointes. Boxes indicate regulatory safety warnings on cardiovascular risk.
doi: 10.1371/journal.pone.0081208.g001
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higher among Northern European Countries as compared to
the remaining areas, with a peak of 0.31 and 0.60 (Norway in
Sweden, respectively). Prothypendyl could be a specific
concern in Austria (0.62) and chlorprothixene in Norway (0.48).
The consumption of antipsychotics included in Group C was
mainly driven by increasing utilization of aripiprazole, especially
in Austria (0.75) and Italy (0.69) in 2010. Flupentixol (0.28 in
Norway and France; 2010 and 2009, respectively) and
perphenazine (0.59 and 0.44 in Norway and Sweden, in 2010)
were appreciably used among Northern European Countries,
melperone among in Central and Eastern European countries
(peak of in 0.37 in Estonia in 2009). Sulpiride was used
consistently across Europe, especially among Central and
Eastern European Countries (0.41 in Croatia in 2010, where
the consumption of promazine was also appreciable at 1.62).
Figure 3 provides a drug-by-drug consumption of
antipsychotics included in Group A. The use of these agents
grew in all 12 Countries. In Serbia, the increment was caused
by risperidone (+1.09); in France by olanzapine and risperidone
(+1.84 and +1.47, respectively), whereas in 9 of the remaining
Table 3. Cross National Comparison: overview of drug utilization data on antipsychotics with at least one spontaneous report
for the events of interest.
Antipsychotics LIT EST SLO SER CRO ITA FRA AUT SPA SCO NOR SWE
cyamemazine ─ ─ ─ ─ ─ ─ 2.74 ─ ─ ─ ─ ─
olanzapine 1.25 0.73 2.34 0.04 1.60 1.96 1.71 1.53 2.53 2.05 2.89 1.97
amisulpride 0.38 0.06 0.26 ─ 0.01 0.20 0.76 0.33 0.38 0.41 0.12 ─
chlorpromazine ─ 0.17 ─ 0.37  0.15 0.06  0.03 0.59 0.08 0.01
clozapine 0.23 0.39 0.60 0.52 0.70 0.42 0.16 0.41 0.28 0.03 0.61 0.54
haloperidol 0.76 0.93 1.01 1.07 1.36 1.61 1.43 0.58 0.70 0.35 0.39 0.53
quetiapine 0.72 0.68 1.15 ─ 0.54 1.72 ─ 1.35 1.30 0.82 1.20 0.64
risperidone 0.65 0.46 1.59 1.02 0.85 0.91 2.46 1.38 2.41 0.76 0.85 1.05
ziprasidone 0.22 ─ 0.14 ─ 0.09 0.03 ─ 0.28 0.38 ─ 0.28 0.18
bromperidol ─ ─ ─ ─ ─ 0.05 ─ ─ ─ ─ ─ ─
chlorprothixene ─ 0.32 ─ ─ ─ ─ ─ 0.16 ─ ─ 0.48 0.03
droperidol ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
fluphenazine 0.11 0.01 1.87 0.83 0.67 0.41 1.00  0.35 0.09 0.02 0.06
levomepromazine ─ 0.09 0.15 2.58 0.19 0.08 0.16 0.12 0.12 0.02 0.34 0.20
prothipendyl ─ ─ ─ ─ ─ ─ ─ 0.89 ─ ─ ─ ─
zuclopenthixol 0.11 0.33 0.34 0.03 0.06 0.14 0.37 0.11 0.17 0.31 0.50 0.61
paliperidone ─ ─ 0.08 ─ ─ ─ ─ ─ ─ ─ ─ 0.03
aripiprazole 0.17 0.16 0.39 ─ ─ 0.43 0.37 0.42 0.41 0.25 0.41 0.41
pimozide ─ ─ ─ ─ ─ 0.07 0.09 0.02 0.05 0.02 ─ 0.01
flupentixol 0.06 0.19 0.13 ─ ─ ─ 0.28 0.03 ─ 0.09 0.28 0.22
loxapine ─ ─ ─ ─ ─ ─ 0.33 ─ ─ ─ ─ ─
melperone 0.13 0.39 ─ ─ ─ ─ ─ 0.14 ─ ─ ─ 0.03
perazine ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
periciazine ─ ─ ─ ─ ─ 0.05 0.15 ─ 0.05 0.02 ─ ─
perphenazine ─ 0.06 ─ ─ ─ 0.04 0.01 ─ 0.11 0.01 0.66 0.45
pipamperone ─ ─ ─ ─ ─ ─ 0.11 ─ ─ ─ ─ ─
prochlorperazine ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ 0.12 0.01
sulpiride ─ 0.05 0.23 ─ 0.35 0.02 0.12 0.05 0.14 0.19 ─ ─
zotepine ─ ─ ─ ─ ─ ─ ─ 0.01 ─ ─ ─ ─
promazine ─ ─ 0.34 ─ 1.59 0.19 ─ ─ ─ 0.02 ─ ─
acepromazine ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
asenapine ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
tiapride 0.28 ─ ─ ─ ─ 0.05 0.42 0.15 0.02 ─ ─ ─
trifluoperazine ─ ─ ─ ─ ─ 0.01 ─ ─ 0.03 0.09 ─ ─
sultopride ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
levosulpiride ─ ─ ─ ─ ─ 0.03 ─ ─ ─ ─ ─ ─
pipotiazine ─ ─ ─ ─ ─ ─ 0.18 ─ 0.03 ─ ─ ─
total 5.07 5.04 10.62 5.40 8.01 8.57 12.91 7.96 9.49 6.12 9.23 7.02
─: no detectable use (i.e., DID<0.01, see methods).
Data are expressed in terms of mean DID for the 2005-2010 period, with the following exceptions: Estonia (2006-2010), Italy (2006-2010), France (2005-2009), Serbia
(2006-2010), Spain (2006-2010) and Sweden (2007-2010).
doi: 10.1371/journal.pone.0081208.t003
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Figure 2.  Antipsychotic utilization according to signal characterization: 2005 (Panel A) versus 2010 (Panel B).  Countries
were ranked by magnitude of 2010 antipsychotic consumption. Percentage: consumption of antipsychotics classified as group D/
total antipsychotic consumption. In parenthesis changes in use of group D compounds (absolute values); + = increment in
consumption; - = decrease in consumption.
doi: 10.1371/journal.pone.0081208.g002
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11 Countries, the trend was mostly driven by quetiapine (from
+0.50 in Sweden to +1.40 in Austria). Olanzapine was
consistently used across all Countries except in Serbia (0.07 in
2010), reaching 2.96 DID in Norway (2010) and showing
increasing consumption in all Countries (+1.84 in France).
Cyamemazine was selectively used only in France with large
extent (2.81 in 2009).
Discussion
The 7-year-period analysis of FAERS characterized 35
antipsychotics with potential torsadogenic signal: 9 of them
fulfilled all pharmacovigilance criteria to be labeled as very
strong torsadogenic signals (i.e., Group A), with cyamemazine
as the only agent currently not included in Arizona CERT lists
(as of January 4th, 2013). Although the validity of the approach
should be balanced against inherent limitations of spontaneous
reporting system (see paragraph below), several issues may
suggest its potential applicability in ranking torsadogenic
signals for prioritization. For instance, the inclusion of
antipsychotics already labeled in AZCERT lists in Group A
such as haloperidol confirms the ability of our
pharmacovigilance approach to accurately confirm actual
safety signals. In addition, the case of cyamemazine underlines
the sensitivity of the applied search strategy in revealing also
Country-specific serious safety concerns from international
archives such as FAERS; as a matter of fact, 96.5% of reports
were submitted by France. Notably instead, quetiapine and
risperidone received ¾ of reports from US despite being largely
used in Europe. Demonstrating the validity of this
pharmacovigilance approach to categorize torsadogenic
signals is beyond the primary aim of this study and is
correlated not only to the magnitude of drug use and its
marketing penetration, but also to the efficiency of national
pharmacovigilance systems, which may vary among Countries.
Although, to the best of our knowledge, no study addressed
this issue in FAERS, recent investigations in WHO-Vigibase
and Eudravigilance found that 85% of reports were submitted
by high-income Countries [34], with a commendable trend
towards increased reporting activity of several national
databases during recent years [35]. Because FAERS reports
were mostly submitted by US and European high-income and
upper middle-income Countries, we believe that FAERS data
are highly informative of the global pattern of torsadogenic
events. From a pharmacological standpoint, six out of ten in
Group A are SGAs, which were originally perceived as safer in
terms of torsadogenic potential [14]. Our findings, therefore,
seem to challenge this conventional belief and are also in line
with a recent multiple-treatment meta-analysis [36], thus
making FAERS a reliable pharmacovigilance source to
provisionally rank drugs for their TdP Liability.
The Cross National Comparison on drug utilization
highlighted an increasing exposure to antipsychotics across
Europe, and found a peak of 13.99 DID in France in 2009, with
appreciable differences in population exposure among the
various European Countries. In 2010, the largest variation was
recorded for Group A drugs: from 3.68 DID (Serbia) to 10.25
(France). These differences may at least partially be explained
by local prescription habits, access to drugs e.g., hospital vs
ambulatory, and differences in copayment levels especially
among Central and Eastern European Countries [37,38]. In
Serbia, the utilization of levomepromazine (3.78 DID in 2010)
requires careful consideration, although it should be
acknowledged that data from the Republic of Serbia included
all reimbursed data (i.e., also hospital data). It is interesting to
observe that our findings from Serbia are in line with past
surveillance figures on outpatient consumption (2000-2004
period) [39], but differed from the most recent investigation
(2005), which recorded 18.3 DID of antipsychotic consumption,
including also hospital data [40]. The use of different data
sources and providers could potentially explain these apparent
inconsistencies. Fluphenazine is also largely used in Slovenia
(1.63 in 2010). These findings may partially explain differences
observed with a previous drug utilization study in Slovenia,
which found lower antipsychotic consumption as compared to
the Scandinavian Countries [41]. The case of olanzapine is a
matter of concern for several Countries, especially in the light
of increasing consumption throughout the period of interest. By
contrast, in Serbia, only rarely is olanzapine dispensed to
patients. When considering population exposure, fractional
values should be also taken into account: for instance,
although the overall consumption of antipsychotics is the
highest in France, the use of Group D agents is also important
(11.2% as compared to the overall use). Therefore, we believe
that authorities in France should look more closely at
prescription of Group A agents and consider policies such as
educational interventions to reduce their utilization. Serbia
should consider implementing measures to balance the
utilization of Group B drugs (especially levomepromazine)
towards potential therapeutic alternatives in Group D. Any
strategy to reduce torsadogenic risk by APs should primarily
consider that, especially in psychiatry, the overall risk-benefit
profile of each agent is strongly influenced by specific patient
response, both in terms of efficacy and safety. Consequently,
health authorities should highlight all available information
regarding the effectiveness and safety of different APs to help
physicians make more informed decisions.
From regulatory and clinical standpoints, cross-national
comparisons on drug utilization research allow the identification
of specific scenarios requiring close post-marketing
surveillance [42]. These studies should be encouraged by
regulators and clinicians, especially for medicines intended for
chronic use such as antipsychotics, because of the insufficient
predictivity of premarketing investigations as compared to the
real clinical setting [43]. Our study found some specific
concerns that are exclusive for a given Country, which we
believe require further research and discussion: this is the case
for cyamemazine in France and prothipendyl in Austria. In
particular, in the light of the high-quality pharmacovigilance
system in France, we believe that ad hoc pharmacovigilance
studies should be encouraged: detailed case-by-case
assessment of reports and accurate calculation of reporting
rates. Notably, different cross-sectional surveys [44-46] already
explored the actual pattern of use (e.g., therapeutic indication
and targeted population) and found that cyamemazine was one
of the most frequently prescribed antipsychotic by virtue of its
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Figure 3.  Country-by-Country Comparison in antipsychotic utilization included in Group A: 2005 versus 2010.  Abscissa:
DID. OLA: olanzapine; ZIP: ziprasidone; RIS: risperidone; QUE: quetiapine; HAL: haloperidol; CLO: clozapine; CHL:
chlorpromazine; AMI: amisulpride; CYA: cyamemazine (shown only in France).
doi: 10.1371/journal.pone.0081208.g003
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anxiolytic and sedative properties, in the context of mood
disorders and other psychiatric disorders. The use of
prothipendyl in Austria is in line with a study showing that it was
the most frequently prescribed antipsychotic in nursing homes
[47]. Further pharmacoepidemiological studies are needed to
fully elucidate the prescribing pattern of prothipendyl.
From a research standpoint, drug utilization data have been
shown to be a valuable data source for ecological studies [48].
Here, drug utilization data allow to approach
pharmacovigilance data (derived by the clinical pharmacology
perspective of single patients) in a population risk perspective.
Specifically, we believe the role of drug utilization data is
crucial in (1) measuring the public health impact of ADRs
(mapping the pro-arrhythmic risk of a given drug), (2)
interpreting pharmacovigilance data and (3) calculating the
reporting rate (i.e., raw risk estimates after performing the
causality assessment of cases obtained only from efficient
pharmacovigilance systems) [49].
The large and steadily increasing use of antipsychotics in
Europe, with considerable differences among Countries,
implies different population exposure with different levels of
risk. This joint analysis, although preliminary, demonstrates the
synergy between drug utilization and adverse event databases
to alert health policy personnel of potential future activities to
reduce ADRs, especially for drugs associated with very strong
torsadogenic signal. Both ad hoc initiatives (e.g., haloperidol
[50,51]) or more general approaches for an entire
pharmacological class could be hypothesized [52].
Drug utilization data also represents a key way forward to
interpret pharmacovigilance data: the so-called “targeted
pharmacovigilance approach” [27]. A list of antipsychotics that
may tentatively be considered to carry a low torsadogenic risk
should be based on: (a) “negative” pharmacovigilance data
(i.e., none of the aforementioned criteria fulfilled); (b) long time
on the market (at least 10 years); (c) detectable use (i.e., at
least 0.01 DID) in at least 3 Countries. Based on our data, no
antipsychotics met all these criteria and, therefore, they appear
to carry an inherent torsadogenic risk. However, within Group
D, the use of tiapride should not be overlooked: 0.39 in France
(2009), 0.36 in Lithuania (2010), with 7 cases of VA/SCD
recorded in FAERS (only criterium 4 was fulfilled) and 104 total
reports.
From an epidemiological standpoint, the large utilization of
antipsychotics is a well known pharmaco-epidemiological
burden, also for off-label indications [9]. Several studies on US
and Canada prescriptions examined the impact of regulatory
safety warnings and found only a slight decrease or even an
increase of the antipsychotic use (especially SGAs in patients
with dementia) [20-23]. Our data are also in line with a recent
analysis on Australian data, which revealed a +217.7%
increase in atypical antipsychotic dispensation over the
2000-2011 period, with olanzapine as the most frequently
dispensed agent [53]. A previous European Cross National
Comparison survey, performed on 12 Countries over the
2000-2005 period, highlighted large variability in antipsychotic
exposure, but reported only a slight increase in their
consumption [40].
Therefore, our study found that, notwithstanding recent
evidence and regulatory safety warnings, the use of
antipsychotics (and especially SGAs) continues to rise in
Europe. Consequently, we believe there is need to implement
effective initiatives of risk management to reduce antipsychotic
medication prescriptions or promote appropriateness.
Limitations of the study
The clinical implications of this study should be carefully
evaluated in the light of limitations affecting both
pharmacovigilance and drug consumption data.
The analysis of spontaneous reports does not allow establish
causality and is affected by the under-reporting; thus, no
incidence can be calculated. In addition, there are several
external factors that may influence the reporting [54-56]. In this
respect, a number of safety warnings on the cardiovascular risk
have been posted by the FDA that may have stimulated
reporting: in 2005, SGAs received an alert on the risk of death
in elderly patients with behavioral disturbances (http://
www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/
DrugSafetyInformationforHeathcareProfessionals/
PublicHealthAdvisories/ucm053171.htm), extended in June
2008 (FDA) (http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/
ucm107211.htm) and November 2008 (EMA) (http://
www.ema.europa.eu/docs/en_GB/document_library/Report/
2010/01/WC500054057.pdf) to FGAs; in 2007, haloperidol
received a specific FDA alert on the risk of TdP/QT
prolongation with relevant label changes (http://www.fda.gov/
Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/
DrugSafetyInformationforHeathcareProfessionals/
ucm085203.htm).
Although also serious and rare European reports are
submitted to the FDA, our data may be affected by specific
drug marketing penetration (e.g., drugs only marketed in
Europe). In addition, the characterization of signals is dynamic
so that a given antipsychotic may change groups depending on
the availability of new pharmacovigilance data over time.
This study attempted to overcome the lack of information on
exposed population in spontaneous reporting sources, by
linking FAERS findings with drug consumption. These two data
sources are independent and provide different perspectives,
although they could be theoretically related and influenced by
each other. As a matter of fact, it should be acknowledged that
antipsychotics included in Group A are also largely and
consistently used across Europe.
Although pharmacovigilance and drug utilization data
sources did not cover the same geographical area (only
Europe for drug utilization and theoretically all Countries for
pharmacovigilance), we used these two dataset for different
purposes: (a) FAERS, the largest public pharmacovigilance
database, to accurately classify and characterize torsadogenic
signal by antipsychotics, and (b) European drug utilization data
to map the overall antipsychotic use (i.e., estimate the
European population exposure).
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Finally, with the exception of Scandinavian Countries [57]
and now Scotland, record-linkage analyses with actual
therapeutic indications, diagnoses and other clinical variables
are challenging through reimbursement prescription databases.
Nonetheless, we did not aim to assess whether differences
arise among labeled and unlicensed indications or evaluate
patients’ characteristics.
Conclusions
This targeted pharmacovigilance approach prioritized a
group of 9 APs with a very strong torsadogenic signal and
provide evidence that the European population is still largely
exposed to them, especially SGAs. Notwithstanding the
regulatory safety concerns, the use of SGAs has started to rise
again among a number of European Countries during the last
6-year period. This potentially poses a public health concern in
the acute management of arrhythmia-related events when
antipsychotics are used outside the hospital setting.
This Cross National Comparison study highlighted (a)
considerable differences in the level of population risk among
the different European Countries in 2010 and (b) specific drug-
or Country-related scenarios that should be considered by
regulators and clinicians to establish tools for monitoring
appropriateness: levomepromazine in Serbia, fluphenazine in
Slovenia, cyamemazine in France, olanzapine across Europe.
We believe that a routine joint approach between
spontaneous reporting and drug utilization analyses together
with synergy among healthcare professionals, academia,
regulators and industry should be encouraged for future
pharmacovigilance activities such as post-authorization safety
studies.
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